- Menu
- 1. Lipides...
- 2. Exposé
- 3. No potential conflicts of interest
- 4. Cardiovascular disease in Switzerland
- 5. Maladies cardiovasculaires: fardeau humain et économique
- 6. Cardiovascular diseases in Switzerland
- 7. Cardiovascular diseases in Switzerland
- 8. Cardiovascular diseases in Switzerland
- 9. Facteurs de risque et maladies CV
- 10. Lipides et maladies CV
- 11. Causative factors vs bystanders
- 12. Transport and synthesis of lipids
- 13. Structure of lipoproteins
- 14. Structure of lipoproteins
- 15. The central role of arterial retention of LDL-C in the pathogenesis of atherosclerosis
- 16. The central role of arterial retention of LDL-C in the pathogenesis of atherosclerosis
- 17. Lipoprotein(a) causally related to CVD-risk
- 18. Remnant cholesterol causally related to CVD-risk
- 19. Exposé
- 20. Concept change I: Use combination therapy
- 21. Concept change II: Start Early
- 22. Concept change II: Start Early
- 23. Concept change III: Treat (much more) aggressive
- 24. Exploratory analysis of patients with LDL-C <0.26 mM
- 25. Exposé
- 26. LDL-C has both a causal and a cumulative effect on CHD risk
- 27. Slide 27
- 28. Genetic-therapy to reduce blood-lipids-levels
- 29. Comparison of drug technologies for reducing plasma lipids and lipoproteins
- 30. Lowering PCSK9 with siPCSK9
- 31. Approaches to reduce LDL-C levels
- 32. Lowering Lp(a) with apo(a)-antisense
- 33. Effect of Galnac apo(a) antisense
- 34. 'Remnant' cholesterol is next on the list
- 35. 'Remnant' cholesterol is next on the list
- 36. Opportunities and challenges for the future
- 37. Gene therapy is next on the list
- 38. Slide 38
- 39. Lipid Residual Cardiovascular risk Future Personal Prevention
- 40. Te future of lipid-lowering strategy to reduce cardiovascular disease
- 41. Consultation "Lipides" aux HUG
- 42. Slide 42